Astomin (Dimemorfan Phosphate Tablets) is a non-narcotic central antitussive. First approved in Japan in 1974, it has been widely used for relieving cough symptoms due to its high safety and low abuse risk.

Dosage and Administration of Astomin (Dimemorfan Phosphate Tablets)

Regular Dosage Guidelines

For adults (15 years old and above): The recommended dosage is 1–2 tablets (equivalent to 10–20mg dimemorfan phosphate) per dose, three times a day.

The tablets must be swallowed whole. It is recommended to take them after meals to reduce gastrointestinal reactions.

Administration Details and Reminders

Special attention should be paid to the PTP aluminum foil packaging. Patients must be instructed to remove the tablets from the aluminum foil before taking.

Accidental ingestion of the aluminum foil packaging may cause its sharp edges to pierce the esophageal mucosa, and even lead to perforation and mediastinitis or other serious complications.

Dosage Adjustment of Astomin (Dimemorfan Phosphate Tablets)

Regular Adjustment Principles

Dosage should be individually adjusted based on the patient’s age, severity of symptoms, and treatment response.

For patients with mild cough or those requiring long-term treatment, the lower dosage (10mg per dose) is preferred, and adjusted gradually according to symptom control.

If symptoms do not improve after one week of continuous medication, the diagnostic plan should be re-evaluated.

Treatment Cycle Management

The course of treatment for acute cough generally does not exceed 2 weeks; chronic cough requires regular efficacy assessment.

Patients with hepatic insufficiency do not need explicit dosage adjustment, but enhanced monitoring is recommended.

Due to the lack of clear research data, dosage adjustment should be cautious in patients with renal impairment.

Use in Special Populations for Astomin (Dimemorfan Phosphate Tablets)

Geriatric Patients

Due to age-related decline in physiological functions, drug clearance rate may decrease in the elderly, so special attention should be paid to dose reduction.

The starting dosage is recommended to be the lower limit of the standard dose (10mg per dose), with close observation of neurological reactions such as dizziness and drowsiness.

Pregnant and Lactating Women

Pregnant women or women of childbearing potential should use this medication only when the therapeutic benefits are clearly greater than the risks.

Lactating women need to comprehensively weigh the treatment needs and breastfeeding benefits. It is recommended to suspend breastfeeding during medication or choose alternative treatment plans.

Pediatric and Adolescent Populations

Currently, the package insert does not specify the medication standards for children under 15 years old, so this age group is not recommended to use the drug.

Adolescents aged 15–18 should take the lower limit of the adult dosage, with enhanced medication monitoring.